Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib and Durvalumab in Advanced Hepatocellular Cancer
NCT07226063Phase 2Not yet recruiting
- Start
- May 2026
- Primary completion
- Feb 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of zanzalintinib in hepatocellular carcinoma (HCC). Planned start May 2026; status: not yet recruiting.
02
Drugs
zanzalintinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07226063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226063.